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A bs tr ac t
Background
Respiratory syncytial virus (RSV) infection is associated with subsequent recurrent 
wheeze. Observational studies cannot determine whether RSV infection is the cause 
of recurrent wheeze or the first indication of preexistent pulmonary vulnerability in 
preterm infants. The monoclonal antibody pal i viz u mab has shown efficacy in pre-
venting severe RSV infection in high-risk infants.
Methods
In the double-blind, placebo-controlled MAKI trial, we randomly assigned 429 oth-
erwise healthy preterm infants born at a gestational age of 33 to 35 weeks to receive 
either monthly pal i viz u mab injections (214 infants) or placebo (215 infants) during 
the RSV season. The prespecified primary outcome was the total number of parent-
reported wheezing days in the first year of life. Nasopharyngeal swabs were taken 
during respiratory episodes for viral analysis.
Results
Pal i viz u mab treatment resulted in a relative reduction of 61% (95% confidence in-
terval, 56 to 65) in the total number of wheezing days during the first year of life 
(930 of 53,075 days in the RSV-prevention group [1.8%] vs. 2309 of 51,726 days 
[4.5%] in the placebo group). During this time, the proportion of infants with re-
current wheeze was 10 percentage points lower in patients treated with pal i viz u-
mab (11% vs. 21%, P = 0.01).
Conclusions
In otherwise healthy preterm infants, pal i viz u mab treatment resulted in a signifi-
cant reduction in wheezing days during the first year of life, even after the end of 
treatment. These findings implicate RSV infection as an important mechanism of 
recurrent wheeze during the first year of life in such infants. (Funded by Abbott 
Laboratories and by the Netherlands Organization for Health Research and Devel-
opment; MAKI Controlled Clinical Trials number, ISRCTN73641710.)
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Illness of the lower respiratory tract that is caused by respiratory syncytial virus (RSV) is the most common cause of hospital 
admission in the winter season during the first 
year of life.1 Severe RSV bronchiolitis has been 
associated with an increase in subsequent rates 
of early wheezing,2,3 asthma, and possibly aller-
gic sensitization later in life.4-7 Early childhood 
wheeze after RSV infection has a high prevalence, 
influences quality of life, and generates substan-
tial health care costs.8-11
The pathogenesis of recurrent wheeze after 
RSV infection is still poorly understood. Gern and 
Busse distinguished two nonexclusive relation-
ships between RSV infection and wheezing.12 
First, RSV bronchiolitis may interfere with nor-
mal lung development or immune maturation 
and subsequently cause recurrent episodes of 
wheezing. Second, RSV infection may be the 
earliest stimulus for wheezing in children who 
are predisposed to wheeze by genetic suscepti-
bility or preexisting abnormal lung function at 
birth. A birth cohort study provided limited evi-
dence for a causal relationship between RSV and 
recurrent wheeze, since the timing of birth in 
relationship to the annual winter RSV peak pre-
dicted the risk of recurrent wheeze.13 So far, the 
potential causal role of RSV infection in the de-
velopment of recurrent wheeze is debated, but 
strong empirical evidence is lacking.14,15 Wu and 
Hartert therefore concluded that a randomized 
clinical trial using RSV prophylaxis was war-
ranted to confirm a causal relationship between 
RSV infection and recurrent wheeze.16
We performed the multicenter, double-blind, 
randomized, placebo-controlled MAKI trial to 
investigate the potential causal role of RSV in-
fection in the pathogenesis of wheezing illness 
during the first year of life, using the commer-
cially available monoclonal antibody pal i viz u mab 
(Synagis, MedImmune) against RSV.
Me thods
Patients
From April 2008 through December 2010, we 
enrolled preterm infants (gestational age, 33 to 
35 weeks) in pediatric departments of one uni-
versity and 15 regional hospitals in the Nether-
lands. All the infants were otherwise healthy and 
6 months of age or younger at the start of the 
RSV season. We excluded infants with congeni-
tal heart disease, bronchopulmonary dysplasia, 
Down’s syndrome,17 or other serious congenital 
disorders and infants who required mechanical 
ventilation at birth, who were treated with sur-
factant, or who had physician-diagnosed wheeze 
before the start of the RSV season.
Parents provided written informed consent 
for study participation. The study was conducted 
according to the principles of the Declaration of 
Helsinki (version 2000). A yearly monitoring pro-
gram that followed current Good Clinical Practice 
guidelines was run routinely.
Ethical Issues
Pal i viz u mab is registered but not reimbursed in 
the Netherlands for preterm infants born at a 
gestational age of 33 to 35 weeks. Because RSV 
immunoprophylaxis is effective in preventing 
RSV lower respiratory tract illness in such pre-
term infants,18 our study was marked as a thera-
peutic study. The institutional review board at the 
University Medical Center Utrecht decided that 
the 50% chance of benefit of RSV prevention 
with pal i viz u mab outweighed the risk of moder-
ate side effects caused by the intramuscular ad-
ministration of placebo and the burden of par-
ticipating in this trial. The protocol was reviewed 
and approved by the institutional review board at 
the University Medical Center Utrecht and at each 
participating hospital.
Randomization
Eligible infants were randomly assigned in a 1:1 
ratio to receive either pal i viz u mab (at a dose of 
15 mg per kilogram of body weight) or placebo 
during the winter season (details are provided in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The blinding 
of study-group assignment was performed with a 
randomization list that used a permuted-block 
design, which was generated by an independent 
pharmacist before the start of the trial. The ran-
domization was stratified according to gestational 
age. Blinding was achieved with the use of a pla-
cebo matching the reconstituted pal i viz u mab so-
lution. The researchers who received the logs and 
performed the analyses and the parents were un-
aware of study-group assignments until 1 year of 
follow-up was completed for all participants. The 
research nurses who administered the study drugs 
were aware of study-group assignments because 
it was not feasible to prepare and administer the 
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treatment in a blinded fashion within 3 hours 
after reconstitution. The research nurses were 
trained to reveal no knowledge of the randomiza-
tion to parents and were not involved in the report-
ing of data analyses. The research nurses worked 
with standard operating procedures and were care-
fully instructed to prevent possible unblinding.
Study Outcomes and Follow-up
The primary outcome was number of parent- 
reported wheezing days in the first year of life. 
Using methods identical to those used in our 
previous trial, parents recorded airway symp-
toms, doctor visits, and the use of airway drugs 
in a daily log until their infant was 1 year of 
age.19,20 Instructions for completing the log were 
given during the first home visit, and compliance 
was checked at each subsequent home visit.
Secondary outcomes were the number of days 
with bronchodilator use, the number of RSV in-
fections confirmed by means of a nasopharyngeal 
swab positive for RSV RNA with or without medi-
cal attention, the number of hospitalizations for 
laboratory-proven RSV infection, the number of 
wheezing episodes, and the prevalence of recur-
rent wheeze. Medical attention was defined as a 
visit to either a general practitioner or a hospital. 
A wheezing episode was defined as a respiratory 
episode with wheezing on more than 1 day. The 
interval between two episodes was defined as a 
period of at least 7 days without respiratory symp-
toms. Recurrent wheeze was defined as three or 
more episodes of wheezing during the first year 
of life. A family history of atopy was defined as 
a physician diagnosis of asthma, hay fever, or 
eczema in at least one of the parents.
Laboratory Tests and Follow-up
We defined the post-prophylaxis period as the 
follow-up from 2 months after the last treatment 
administration (three half-lives of pal i viz u mab) 
up to the age of 1 year. In case of respiratory 
symptoms, primary care was left to the general 
practitioner.
Parents were instructed to take a nasopharyn-
geal swab in case of the occurrence of respira-
tory symptoms with involvement of the upper or 
lower respiratory tract lasting more than 1 day. 
The swab was transported in a viral transport 
medium by regular mail to the laboratory and 
stored at −80°C until polymerase-chain-reaction 
(PCR) assays were performed. The presence of 
RSV RNA was determined by multiplex real-time 
reverse-transcriptase–PCR with the use of previ-
ously published primers and probes for RSV-B21 
and primers and probes for RSV-A that were 
developed in-house (details are provided in the 
Supplementary Appendix).
We determined the presence of 16 respiratory 
viruses and 4 respiratory bacteria using the 
RespiFinder SMART 22 assay (PathoFinder).22 
Positive results on testing for rhinovirus or en-
terovirus are referred to as rhinovirus infection. 
All hospitalizations were evaluated, and any deaths 
were regarded as serious adverse events. Local 
injection-site reactions and physician visits for 
nonrespiratory symptoms were not recorded.
Study Oversight
The academic authors designed and conducted the 
study without input from the study sponsor (Ab-
bott Laboratories, which markets pal i viz u mab) 
other than financial support and donation of the 
pal i viz u mab. All authors vouch for the accuracy 
and completeness of the data reported and for the 
fidelity of this report to the study protocol, avail-
able at NEJM.org.
Statistical Analysis
The sample-size calculation was based on a clin-
ically relevant between-group difference of a mean 
(±SD) of 5±15 wheezing days during the first year 
of life.20,23,24 The predefined target of 226 in-
fants per study group provided a power of at least 
90% to detect a clinically relevant difference in 
wheezing days with the use of an alpha level of 
0.05. Since a typical Poisson distribution for 
probability arose, we used Poisson regression 
analysis to study potential differences in the 
number of days with wheeze.20 Percentages and 
associated 95% confidence intervals of infants 
with wheezing or recurrent wheeze episodes were 
calculated. We used chi-square tests, Student’s 
t-tests, and Mann–Whitney U tests to evaluate 
differences in percentages, mean values, and me-
dian values between the two study groups. All 
analyses were performed on an intention-to-treat 
basis. No imputation of missing data was per-
formed, since the overall amount of missing data 
was less than 10%. Post hoc subgroup analyses 
were performed to assess wheezing days in sub-
groups of children with a family history of atopy 
or asthma. All statistical analyses were performed 
with SPSS software, version 20.0.
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R esult s
Patients
Of 1550 late preterm infants (gestational age, 33 to 
35 weeks) who underwent screening, 429 were 
enrolled in the study (Fig. 1A). The median day 
of birth was August 22 for infants who were en-
rolled in the study, as compared with a median 
day of birth of August 5 for infants who were not 
enrolled. The two study groups were well bal-
anced on the basis of inclusion year, gestational 
age, and birth month. Birth weight, family history 
of atopy, presence of siblings, and other baseline 
characteristics were similar, except for sex (58% 
male infants in the RSV-prevention group vs. 44% 
in the placebo group) (Table S1 in the Supplemen-
tary Appendix). By design, only children with no 
previous wheezing symptoms were enrolled.
A median number of 4 injections during the 
RSV season were administered to infants in the 
RSV-prevention group (range, 1 to 5) and the pla-
cebo group (range, 2 to 5). In the RSV-prevention 
group, 95% of scheduled injections and 89% of 
follow-up of daily logs were completed, as com-
pared with rates of 92% and 88%, respectively, in 
the placebo group. The median follow-up dura-
tion was 10 months (range, 0 to 12) in the two 
study groups.
RSV Infection
We studied the occurrence and severity of RSV 
infection to confirm the efficacy of RSV immuno-
prophylaxis in our study population. We confirmed 
that infants who were treated with pal i viz u mab 
had a lower incidence of RSV-related hospitaliza-
tion than those treated with placebo (0.9% vs. 5.1%, 
P = 0.01).18 The infants who were treated with pal-
i viz u mab also had a lower incidence of medically 
attended nonhospitalized RSV infection (Table 1).
Primary and Secondary Outcomes
The number of days with parent-reported wheeze 
was lower in the RSV-prevention group than in the 
placebo group (Table 2 and Fig. 2). This result 
was consistent for all 3 study years and indepen-
dent of the number of injections of pal i viz u mab 
or placebo. There was an absolute reduction of 
2.7 percentage points in rates of wheezing in the 
RSV-prevention group versus the placebo group 
(930 of 53,075 days [1.8%] and 2309 of 51,726 
days [4.5%], respectively), for a relative reduction 
of 61% (95% confidence interval [CI], 56 to 65).
The effect of RSV prevention on the number of 
wheezing days persisted during the post-prophy-
laxis period (i.e., starting at 2 months after the 
last injection), for a relative reduction of 73% 
(95% CI, 66 to 80). Similarly, there was a de-
crease in the number of wheezing days outside 
the RSV season in the RSV-prevention group 
(Table 2). Among children with any proven RSV 
infection, there was no significant between-group 
difference in the incidence of wheezing (23% in 
the RSV-prevention group and 30% in the pla-
cebo group) or in the mean number of wheezing 
days during the first year of life (8.2 days in the 
RSV-prevention group and 16 days in the placebo 
group). We did not detect RSV reinfection in ei-
ther group.
The proportion of infants with recurrent 
wheezing was lower in the RSV-prevention group 
than in the placebo group (11.2% vs. 20.9%, 
P = 0.005) (Table 3). Similarly, the proportion of 
infants using bronchodilators was lower in the 
RSV-prevention group than in the placebo group 
(13% vs. 23%, P<0.001). The effect of RSV pre-
vention on the total number of wheezing days 
was not significantly different (P = 0.89) in chil-
dren without a family history of atopy (72% re-
duction; 95% CI, 65 to 79), as compared with 
those with a family history of atopy (54% reduc-
tion; 95% CI, 47 to 60). A similar effect of RSV 
prevention was seen in children without and with 
parental asthma (68% reduction [95% CI, 62 to 
73] vs. 35% reduction [95% CI, 23 to 47]). The 
total numbers of respiratory episodes were simi-
lar in the two study groups. However, we found 
more coinfections during nonwheezing episodes 
in the RSV-prevention group than in the placebo 
group (101 of 236 swabs [43%] vs. 63 of 197 
swabs [32%], P = 0.02) (Fig. 1B).
Adverse Events
The proportion of patients with serious adverse 
events was lower in the RSV-prevention group 
than in the placebo group. We observed 32 hos-
pitalizations in 27 children (12.6%) in the RSV-
prevention group, as compared with 52 hospital-
izations in 47 children (21.9%) in the placebo 
group (P = 0.04). Reasons for hospitalization in 
the RSV-prevention group were RSV infection (in 
2 patients), other respiratory tract illness (in 6), 
gastroenteritis (in 6), surgery (in 6), failure to 
thrive (in 6), and other reasons (in 6). Reasons for 
hospitalization in the placebo group were RSV 
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A BEnrollment Respiratory Episodes and Virologic Results
1347 Were eligible
1550 Late preterm
infants screened
203 Did not meet
criteria
492 Were included at
birth
855 Did not provide
consent
429 Underwent
randomization
63 Were excluded
before randomi-
zation
429 Were included in the
intention-to-treat analysis
1109 Total respiratory
episodes
214 Were assigned to
receive palivizumab
137 Were wheezing
episodes
972 Were nonwheezing
episodes
82% Accompanied
runny nose
67% Accompanied
coughing
26% Accompanied
fever >38.5°C
13% Accompanied
dyspnea
35 (26%) Swabs
were taken
236 (24%) Swabs
were taken
81 (30%) Swabs
were taken
197 (22%) Swabs
were taken
1144 Total respiratory
episodes
215 Were assigned
to receive placebo
266 Were wheezing
episodes
878 Were nonwheezing
episodes
81% Accompanied
runny nose
69% Accompanied
coughing
27% Accompanied
fever >38.5°C
13% Accompanied
dyspnea
23 (66%) Were positive
for a pathogen
4 (11%) Were positive
for multiple patho-
gens
2 (6%) Were identified
as RSV
8 (23%) Were identi-
fied as rhinovirus
7 (20%) Were identi-
fied as coronavirus
3 (9%) Were identified
as adenovirus
3 (9%) Were identified
as bocavirus
2 (6%) Were identified
as influenza virus
1 (3%) Was identified
as PIV1-4
1 (3%) Was identified
as M. pneumoniae
218 (92%) Were posi-
tive for a pathogen
101 (43%) Were posi-
tive for multiple
pathogens
8 (3%) Were identi-
fied as RSV
175 (74%) Were identi-
fied as rhinovirus
33 (14%) Were identi-
fied as coronavirus
51 (22%) Were identi-
fied as adenovirus
45 (19%) Were identi-
fied as bocavirus
2 (1%) Were identi-
fied as influenza
virus
24 (10%) Were identi-
fied as PIV1-4
6 (3%) Were identi-
fied as hMPV
1 (<1%) Was identi-
fied as M. pneu-
moniae
47 (58%) Were positive
for a pathogen
4 (5%) Were positive
for multiple patho-
gens
15 (19%) Were identi-
fied as RSV
15 (19%) Were identi-
fied as rhinovirus
7 (9%) Were identi-
fied as coronavirus
7 (9%) Were identified
as adenovirus
2 (2%) Were identified
as bocavirus
4 (5%) Were identified
as PIV1-4
1 (1%) Was identified
as hMPV
185 (94%) Were posi-
tive for a pathogen
63 (32%) Were posi-
tive for multiple
pathogens
15 (8%) Were identi-
fied as RSV
140 (71%) Were identi-
fied as rhinovirus
17 (9%) Were identi-
fied as coronavirus
36 (18%) Were identi-
fied as adenovirus
29 (15%) Were identi-
fied as bocavirus
6 (3%) Were identi-
fied as influenza
virus
13 (7%) Were identi-
fied as PIV1-4
7 (4%) Were identi-
fied as hMPV
1 (1%) Was identi-
fied as pertussis
1 (1%) Was identi-
fied as M. pneu-
moniae
214 Were assigned to
receive palivizumab
215 Were assigned
to receive placebo
14 Were lost to follow-
up
1 Had physician-
diagnosed
wheeze before
start
1 Had RSV hospi-
talization before
start
10 Were withdrawn
before treatment
2 Were withdrawn
after ≥1 treat-
ment
20 Were lost to follow-
up
1 Had physician-
diagnosed
wheeze before
start
1 Had RSV hospi-
talization before
start
12 Were withdrawn
before treatment
6 Were withdrawn
after ≥1 treat-
ment
Figure 1. Enrollment, Number of Respiratory Episodes, and Results of Virologic Analyses.
Panel A shows enrollment and study outcomes for the 429 infants who were included in the intention-to-treat analysis. Panel B shows 
the total number of respiratory symptoms, which were based on parent records. A respiratory episode was defined as an episode of at 
least 2 consecutive days of upper or lower respiratory symptoms. Parents were instructed to take a nasopharyngeal swab on the second 
day of every respiratory episode. Respiratory syncytial virus (RSV) was detected with the use of in-house real-time reverse-transcriptase–
polymerase-chain-reaction assays, and the RespiFinder SMART 22 assay was used for the detection of adenovirus, bocavirus, Bordetella 
pertussis, Chlamydia pneumoniae, coronavirus (229E, HKU1, NL63, and OC43), human metapneumovirus (hMPV), influenza virus type A, 
influenza virus A(H1N1)pdm09, influenza virus type B (influenza virus), Legionella pneumophila, Mycoplasma pneumoniae, parainfluenza 
virus types 1 through 4 (PIV1-4), RSV types A and B (RSV), and rhinovirus or enterovirus (rhinovirus).
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infection (in 11 patients), other respiratory tract 
illness (in 6), gastroenteritis (in 10), surgery (in 
13), failure to thrive (in 8), and other reasons (in 
4). There were no deaths.
Discussion
In this proof-of-concept study, treatment with a 
monoclonal antibody for RSV prevention in late 
preterm infants greatly reduced the number of 
parent-reported wheezing days during the first 
year of life, even after the end of therapy and 
outside the RSV season. RSV prevention reduced 
wheezing, but wheezing was not eliminated. RSV 
prevention was associated with a relative reduc-
tion of 61% in the number of wheezing days, a 
finding that shows that RSV infection is an im-
portant mechanism in the pathogenesis of wheez-
ing morbidity in this specific population.
Our results are in line with other studies that 
acknowledge the relationship between RSV bron-
chiolitis and recurrent wheeze.4,7,9,25-27 Wu et al.13 
found that the timing of birth date with respect 
to the peak of the winter bronchiolitis season 
was related to the risk of asthma. These findings 
suggest that asthma is most likely to develop in 
infants who are at highest risk for severe viral 
bronchiolitis. However, other studies have argued 
against RSV as the cause of pulmonary damage 
and subsequent early childhood wheezing.2 The 
role of RSV in the development of asthma re-
mains controversial, and our data cannot provide 
evidence in this discussion.28 A previous non-
randomized trial suggested that the prevention 
Table 1. Proportion of Infants with Proven Respiratory Syncytial Virus (RSV) Infection.*
Variable
Palivizumab
(N = 214)
Placebo
(N = 215)
Absolute Risk  
Reduction†
Relative Risk  
Reduction
(95% CI)† P Value
no. (%) percentage points %
Total RSV infection 10 (4.7) 30 (14.0) 9.3 67 (27 to 107) 0.001
Hospitalization for RSV infection 2 (0.9) 11 (5.1) 4.2 82 (18 to 157) 0.01
Medically attended RSV infection without  
hospitalization
2 (0.9) 10 (4.7) 3.7 80 (11 to 161) 0.02
RSV infection without medical attention 6 (2.8) 9 (4.2) 1.4 33 (−56 to 126) 0.40
* Medical attention was registered during the home visits and reported by parents on the daily log.
† The absolute and relative values for risk reduction are for the palivizumab group as compared with the placebo group.
Table 2. Days with Wheezing in the First Year of Life.*
Variable Palivizumab (N = 214) Placebo (N = 215)
Absolute  
Reduction†
Relative Risk  
Reduction (95% CI)†
Total Log 
Days
Total 
Symptom 
Days
Incidence  
per Day
Total Log 
Days
Total 
Symptom 
Days
Incidence  
per Day
no. % no. %
no. of  
symptom days %
Days with wheezing
First year of life 53,075 930 1.8 51,726 2309 4.5 1379 61 (56–65)
<2 mo after prophylaxis 28,455 666 2.3 28,220 1382 4.9 716 52 (46–59)
≥2 mo after prophylaxis 24,620 264 1.1 23,506 927 3.9 663 73 (66–80)
During RSV season‡ 26,176 646 2.5 26,081 1348 5.2 702 52 (46–59)
Outside RSV season‡ 26,899 284 1.1 25,645 961 3.7 677 73 (66–80)
* The incidence of wheezing was calculated as the number of days with parent-reported airway symptoms divided by the number of log days 
during follow-up. P<0.001 for all comparisons except P = 0.006 for the category of less than 2 months after the end of prophylaxis.
† The values for absolute reduction and relative risk reduction are for the palivizumab group as compared with the placebo group.
‡ The RSV season was defined as October 1 to March 31.
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of lower respiratory tract illness caused by RSV 
reduced subsequent recurrent wheeze in infants 
without a family history of atopy but showed no 
effect in infants with a family history of atopy.29,30 
We found that RSV prevention was associated 
with reduced wheezing in the first year of life, 
regardless of whether there was a family history 
of atopy. Our study underlines the important role 
that RSV plays in the pathogenesis of recurrent 
wheeze. We hypothesize that RSV primarily causes 
direct pulmonary epithelial damage and local im-
munologic alterations in the lungs, leading to long-
term airway hyperresponsiveness and wheezing.
A study in mice showed that RSV causes per-
sistent airway hyperresponsiveness, chronic lung 
inflammation, and histopathological abnormali-
ties.31,32 Altered immune-response patterns have 
been described after RSV infection. Studies in 
mice and humans have suggested that local pro-
duction of interleukin-10 during RSV infection is 
a key mechanism in the development of recurrent 
wheeze and airway hyperresponsiveness, although 
mechanisms independent of interleukin-10 have 
also been described.19,33-36 We believe that altera-
tions to the pulmonary environment and immu-
nologic phenotype caused by RSV infection in 
early life eventually lead to long-term remodel-
ing of the pulmonary system and hyperrespon-
siveness to respiratory viruses and nonspecific 
stimuli.
In our study, the numbers of respiratory epi-
sodes were similar in the two study groups. How-
ever, in the RSV-prevention group, we found more 
coinfections than in the placebo group. Previous 
studies have not addressed the effect of pal i viz-
u mab on the acquisition or clearance of respira-
tory viruses other than RSV. RSV bronchiolitis 
is followed by a robust inflammatory response 
in the airways, which may persist for more than 
1 month.37 We speculate that this inflammatory 
response, including production of interferons, 
transiently protects against subsequent viral in-
fection, resulting in fewer coinfections.38,39 More 
research is needed to unravel how respiratory vi-
ruses interact at the mucosal level.
The major strength of our study is the ran-
domized design, which precludes bias from se-
lection or confounding and which subsequently 
provided unbiased and conclusive evidence re-
garding the mechanism of RSV infection in the 
pathogenesis of infant wheezing. Some potential 
limitations should also be discussed. First, par-
ents with an atopic history may have been more 
likely to participate in the study. However, since 
the stratified results did not differ between in-
fants of parents with and those without an atopic 
history, our conclusions are generalizable. Sec-
ond, although nasopharyngeal swabs were ob-
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Figure 2. Cumulative Wheezing Days for 429 Preterm Infants during the First 
Year of Life.
P<0.001 for the comparison between pal i viz u mab and placebo with the use 
of Poisson regression.
Table 3. Infants with Wheezing.*
Variable
Palivizumab 
(N = 214)
Placebo 
(N = 215)
Absolute  
Reduction†
Relative Risk  
Reduction (95% CI)†
Any wheezing — no. of infants (%) 66 (30.8) 101 (47.0) 16.2 34 (14–53)
Wheezing episodes — no. 137 266 129 48 (32–62)
Recurrent wheezing — no. of infants (%) 24 (11.2) 45 (20.9) 9.7 47 (14–80)
* Any wheezing was defined as at least one episode of wheezing during the first year of life. A wheezing episode was defined 
as a respiratory episode with wheezing on more than 1 day. Recurrent wheezing was defined as three or more episodes 
of wheezing during the first year of life. P<0.001 for the between-group comparisons for any wheezing and wheezing 
episodes and P = 0.005 for recurrent wheezing.
† The values for absolute reduction are percentage points, and the values for relative risk reduction are numbers of episodes.
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tained by parents to increase compliance of 
sampling,40 swabs were obtained in approxi-
mately 30% of all respiratory episodes. This is 
similar to the range of percentages (24 to 43%) 
obtained in a study with a similar approach to 
parental swab collection.40,41 Consequently, we 
may underestimate the incidence of RSV infec-
tion. However, since the trial was double-blind 
and randomized, we do not believe this factor 
had an effect on the overall conclusions. Third, 
preterm infants are at higher risk for recurrent 
episodes of wheezing than are term infants.42 
Therefore, we do not know whether our results 
can be generalized to healthy term infants. 
Fourth, we had to rely on parent-reported mor-
bidity data, since no objective measure of wheez-
ing was available. Identifying wheezing is prob-
lematic even for trained clinicians.43,44 However, 
since the parents were unaware of study-group 
assignments, we believe that any misclassifica-
tion of wheezing was random in the two groups.
In summary, we have shown that the admin-
istration of pal i viz u mab for RSV prevention re-
duced the total number of wheezing days in the 
first year of life among preterm infants with a 
gestational age of 33 to 35 weeks. The post-
prophylaxis effect of RSV prevention on wheez-
ing illness is evidence that RSV infection is an 
important mechanism in the pathogenesis of 
wheezing during the first year of life among late 
preterm infants.
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